Artificial intelligence (AI) has been the dominant investment theme on Wall Street in 2026. But as investors look ahead to 2027, several opportunities beyond AI are worth a closer look.
Biotech companies have increasingly directed capital toward oncology treatments in recent years. The sector’s growth outlook may make this an interesting time to consider adding biotech exchange-traded funds (ETFs) to a diversified portfolio.
Now in its seventh month, the war has had a significant impact on two areas in particular: tanker shipping and oil prices, as disruptions involving Iran have constrained traffic through the Strait of Hormuz.
Looking ahead, near-term performance in the generic drug industry is likely to hinge increasingly on execution. Against this backdrop, we highlight three generic drugmakers that appear well positioned to capitalize on this industry evolution.